Ben Hirschler

May 8, 2024 | brunswickgroup.com | Agnes Brandt |Ben Hirschler

An interview with Linklaters’ Georgina Kon, a Partner specializing in complex domestic and international IT, sourcing and information governance matters. As artificial intelligence (AI) rapidly evolves, regulators and policymakers are racing to catch up, seeking to impose the right safeguards without stifling innovation. While every sector is trying to understand the promise and pitfalls of AI, the stakes are especially high in healthcare.

Apr 11, 2024 | brunswickgroup.com | Ben Hirschler |Francesca Scassellati Sforzolini

Europe is updating its rules for how it regulates the pharmaceutical and life sciences industry – with far-reaching implications for its life sciences ecosystem. With the fine print to be negotiated over the coming months, companies still have time to make the case for innovation and ensure Europe doesn’t miss out on a once-in-a-generation opportunity. Are you ready for Europe’s new pharma rules? In the run-up to elections in June, Europe is getting ready to finalise new rules for pharmaceuticals.

Apr 8, 2024 | breathinglabs.com | Ben Hirschler

By Ben HirschlerLONDON (Reuters) - GlaxoSmithKline (GSK.L) is banking on a major clinical trial to revive its flagging respiratory medicine business, with billions of dollars of sales riding on a positive result. Data from the so-called SUMMIT study, designed to show GSK's Breo can prolong lives of patients with chronic lung disease, are expected as early as next month, nine years after a similar study with GSK's older drug Advair failed by a whisker.

Feb 5, 2024 | brunswickgroup.com | Francesca Scassellati Sforzolini |Ayesha Bharmal |Ben Hirschler

An interview with Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry (ABPI). The UK government wants to make the country a life sciences ‘superpower’ by building on its academic strengths and deep pharmaceutical heritage. But in recent years, this enthusiasm has been at odds with a worsening operating environment that has made the UK a particularly tough market to navigate.

Nov 15, 2023 | brunswickgroup.com | Ben Hirschler |Tanisha Carino

An interview with Adrian Hennah, board member of Our Future Health, Oxford Nanopore Technologies, Unilever and J Sainsbury. Genomics is an increasingly important part of modern healthcare, driven by the power of rapid, low-cost DNA sequencing. But to fully realize the potential of genomics – and understand the links between genetics and disease – large-scale population studies are needed to build a complete picture by connecting DNA profiles, lifestyle data and health records.